The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

5 Feb 2019 07:00

RNS Number : 0450P
Motif Bio PLC
05 February 2019
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Exercise of Warrants 

 

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from warrant holders to exercise warrants representing 113,396 ordinary shares of 1p each ("Ordinary Shares") in the Company for total consideration of £36,513.52. The exercise price of all warrants was 32.2p per warrant.

 

Application has been made for the 113,396 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 8 February 2019. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and further to the announcement made on 23 January 2019, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 297,491,023 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

For further information please contact:

 

Motif Bio plc

info@motifbio.com

Graham Lumsden (Chief Executive Officer)

 

 

 

Peel Hunt LLP (NOMAD & BROKER)

+ 44 (0)20 7418 8900

Dr Christopher Golden

 

Oliver Jackson

 

 

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/Helen Cresswell/Lianne Cawthorne

 

motifbio@walbrookpr.com

 

 

 

 

MC Services AG (EUROPEAN IR)

+49 (0) 89 210 2280

Raimund Gabriel

raimund.gabriel@mc-services.eu

 

 

Solebury Trout (U.S. IR)

+ 1 (646) 378-2963

Meggie Purcell

mpurcell@troutgroup.com

 

 

Russo Partners (U.S. PR)

+1 (858) 717-2310 or +1 (212) 845 4272

David Schull

david.schull@russopartnersllc.com

Travis Kruse, Ph.D.

travis.kruse@russopartnersllc.com

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSLFFELFFISIIA
Date   Source Headline
30th Sep 20194:35 pmRNSPrice Monitoring Extension
30th Sep 20192:22 pmRNSHalf-year Report
17th Sep 20194:41 pmRNSSecond Price Monitoring Extn
17th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Sep 20192:57 pmRNSHolding(s) in Company
2nd Sep 20197:00 amRNSAmended Loan and Security Agreement
30th Aug 20194:41 pmRNSSecond Price Monitoring Extn
30th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSNIH to Evaluate Iclaprim Activity against Listeria
1st Aug 20197:00 amRNSAmended Loan and Security Agreement
26th Jul 20197:00 amRNSReceipt of Deficiency Notice from Nasdaq
26th Jul 20197:00 amRNSMotif Bio Confirms Meeting Date with U.S. FDA
19th Jul 20197:00 amRNSMotif Bio-Receipt of Deficiency Notice from Nasdaq
18th Jul 20194:30 pmRNSHolding(s) in Company
15th Jul 20197:00 amRNSUS FDA meeting request and package submitted
28th Jun 20195:13 pmRNSHolding(s) in Company
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:36 pmRNSPrice Monitoring Extension
26th Jun 201912:07 pmRNSSecond Price Monitoring Extn
26th Jun 201912:02 pmRNSPrice Monitoring Extension
24th Jun 20197:00 amRNSMotif Bio Presents New Iclaprim Data - ASM Microbe
20th Jun 20194:35 pmRNSPrice Monitoring Extension
19th Jun 20195:08 pmRNSHolding(s) in Company
18th Jun 20194:05 pmRNSHolding(s) in Company
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20195:52 pmRNSHolding(s) in Company
6th Jun 20197:00 amRNSReceipt of FDA Meeting Minutes
31st May 20193:15 pmRNSResult of AGM
31st May 201910:28 amRNSHolding(s) in Company
29th May 201911:36 amRNSHolding(s) in Company
22nd May 20191:50 pmRNSAGM Statement
22nd May 20197:00 amRNSOrphan Disease Opportunity for Iclaprim
21st May 20197:00 amRNSIclaprim Data presented at ASM Microbe 2019
20th May 20196:14 pmRNSHolding(s) in Company
3rd May 20196:25 pmRNSMeeting with US FDA held as planned
1st May 20197:00 amRNSMotif Signs Agreement with Lamellar Biomedical
26th Apr 20197:01 amRNSNotice of AGM
26th Apr 20197:00 amRNSAppointment of Andrew Powell to Board of Directors
16th Apr 20197:00 amRNSMotif Presents New Iclaprim Data at ECCMID 2019
15th Apr 20197:00 amRNSFiscal Year 2018 Results
4th Apr 20197:00 amRNSMotif Bio to Present Iclaprim Data at ECCMID 2019
2nd Apr 20195:43 pmRNSHolding(s) in Company
1st Apr 20193:28 pmRNSHolding(s) in Company
1st Apr 20192:17 pmRNSHolding(s) in Company
26th Mar 20197:00 amRNSMotif Bio Raises £2.7m (US$3.55m)
25th Mar 20199:49 amRNSProposed Equity Fundraise
20th Mar 20197:00 amRNSHolding(s) in Company
20th Mar 20197:00 amRNSMotif Bio Granted Meeting with U.S. FDA
18th Mar 20197:00 amRNSAppointment of Bruce Williams as Interim Chairman
15th Mar 20197:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.